Freenome
Freenome Maintains CRC Early Detection Timeline as New Biomarker Discovery Studies Progress
The company is using newly raised funds to support a disseminated trial model, which it said will help it keep its plans to finish the study by the end of 2021.
Freenome Closes $270M Series C Financing to Support Early Cancer Detection Trial
The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.
Freenome Begins Prospective Study of Noninvasive Colorectal Cancer Screening Test
The company enters a race to the clinic with several direct competitors, including Guardant Health and CellMax Life, as well as other firms pursuing multi-cancer screening.
The company presented new data on the performance of a multi-pronged liquid biopsy assay in detecting colorectal cancers across a range of clinical stages.